摘要
目的观察孟鲁司特钠联合布地奈德气雾剂对咳嗽变异性哮喘(CVA)患儿血清转化生长因子-β(transforming growth factor-β,TGF-β1)和血清淀粉样蛋白A(serum amyloid A,SAA)水平的影响。方法将60例CVA患儿随机分为观察组和对照组,每组30例,对照组给予抗感染、化痰,对症支持治疗,观察组在对照组基础上加用喷雾吸入布地奈德和孟鲁司特钠睡前口服治疗,治疗结束后,观察两组治疗前后肺活量(VC)、用力肺活量(FVC)和1秒用力呼气容积(FEV1)/用力肺活量(FVC)变化,采用酶联免疫吸附实验(ELISA)法检测血清TGF-β1和SAA水平。结果与治疗前比较,两组患儿治疗后血清TGF-β1和SAA水平显著降低,差异具有统计学意义(P<0.05);与对照组治疗后比较,观察组治疗后血清TGF-β1和SAA水平降低,差异具有统计学意义(P<0.01);治疗后两组FEV1、PEF、FEV1/FVC与治疗前比较差异有统计学意义(P<0.05),与对照组治疗后比较,观察组治疗后FEV1、PEF、FEV1/FVC改善更明显(P<0.05或<0.01)。结论孟鲁司特钠联合布喷雾吸入布地奈德对小儿CVA患者临床疗效显著,能显著改善患者气道炎症反应,值得临床推广使用。
Objective To observe the influence of montelukast combined with budesonide on serum transforming growth factor beta 1（TGF-β1）and serum amyloid A（SAA）in children with cough variant asthma（CVA）.Methods A total of 60 children with CVA were randomly divided into observation group（30cases）and control group（30cases）.The patients in control group were treated by dissolving phlegm,anti-infection,and symptomatic supportive treatment.The patients in observation group got aerosol inhalation of budesonide and montelukast on the basis of control group.Vital capacity（VC）,forced vital capacity（FVC）and FEV1/FVC were observed in two groups before and after treatment.Serum TGF-β1and SAA were detected by ELISA.Results TGF-β1and SAA in both groups significantly reduced after treatment（P〈0.01）.After treatment,TGF-β1and SAA significantly reduced in observation group than in control group（P〈0.05）and FEV1,PEF and FEV1/FVC were significantly improved after treatment in groups,but more obviously in observation group（P〈0.05 or 0.01）.Conclusion Budesonide combined with montelukast can obtain remarkable clinical effect on treating child ren with CVA and obviously improve airway inflammation.It worths clinical application.
出处
《临床荟萃》
CAS
2015年第11期1273-1275,1279,共4页
Clinical Focus
基金
河北省2013年医学科学研究课题计划资助项目(20130198)
